672959-76-1

Upstream product

• 33125-05-2 Boc-D-Phg-OH 
• 95-53-4 o-toluidine 
• 875-74-1 (R)-phenylglycine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 672959-77-2 (R)-2-amino-2-phenyl-N-(o-tolyl)acetamide 
• 672959-78-3 (R)-2-amino-N-(2-methylphenyl)-2-phenylacetamide formic acid salt 

Relevant academic research and scientific papers

Design, synthesis, and insecticidal activities of novel diamide derivatives with alpha-amino acid subunits

A series of diamide derivatives containing α-amino acids were designed and synthesized. These compounds were evaluated for their insecticidal activities against Plutella xylostella, Mythimna separate, Myzus persicae, and Tetranychus cinnabarinus. Most of the title compounds containing an l-phenylglycine skeleton were endowed with good activities at the concentration of 500 mg·L?1. Compounds (R)-A6 showed a potential value for further optimization as an insecticidal lead with the LC50 value of 86.8 mg·L?1.

Small-Molecule Activator of UNC-51-Like Kinase 1 (ULK1) That Induces Cytoprotective Autophagy for Parkinson's Disease Treatment

UNC-51-like kinase 1 (ULK1), the yeast Atg1 ortholog, is the sole serine-threonine kinase and initiating enzyme in autophagy, which may be regarded as a target in Parkinson's disease (PD). Herein, we discovered a small molecule 33i (BL-918) as a potent activator of ULK1 by structure-based drug design. Subsequently, some key amino acid residues (Arg18, Lys50, Asn86, and Tyr89) were found to be crucial to the binding pocket between ULK1 and 33i by site-directed mutagenesis. Moreover, we found that 33i induced autophagy via the ULK complex in SH-SY5Y cells. Intriguingly, this activator displayed a cytoprotective effect on MPP+-treated SH-SY5Y cells, as well as protected against MPTP-induced motor dysfunction and loss of dopaminergic neurons by targeting ULK1-modulated autophagy in mouse models of PD. Together, these results demonstrate the therapeutic potential to target ULK1, and 33i, the novel activator of ULK1, may serve as a candidate drug for future PD treatment.

Target autophagy agonist and application thereof in neurodegenerative disease treating medicine

The invention relates to a target autophagy agonist and application thereof in a neurodegenerative disease treating medicine and belongs to the technical field of neurodegenerative disease resisting pharmacy. The invention aims at providing a compound serving as ULK1 agonist. The compound is prepared from following shown compound or pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof can serve as the ULK1 agonist and has certain neurodegenerative disease resisting activity.

ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS

The present invention relates to compounds of Formula (I) and salts solvates and hydrates thereof. The invention further relates to pharmaceutical compositions containing said compounds and methods of treating neurological and neuropsychistric disorders using said compounds.